(May 6, 2010, Weil Gotshal News)
Biopharm Insight, an independent biotechnology and pharmaceutical intelligence service and database, has determined that Weil, Gotshal & Manges was among the leading legal advisors on biotech and pharmaceutical industry merger & acquisition transactions globally during the first quarter of 2010 and over the prior twelve month period.
Some of Weil's highlighted rankings (based on transaction value) according to BioPharm Insight include:
Trailing 12 Months, March 2010• Global Biotech & Pharma M&A, 1st
• North American Biotech & Pharma M&A, 1st
• European Biotech & Pharma M&A, 2nd
1Q 2010• Global Biotech & Pharma M&A, tie 3rd
• North American Biotech & Pharma M&A, tie 2nd
• European Biotech & Pharma M&A, tie 1st
Some of the firm's most significant recent biotech and pharmaceutical M&A deals have included:
Advising Sanofi-Aventis SA of France in its decision to combine Merial with Intervet/Schering-Plough, Merck & Co.'s animal health business. This joint venture follows Sanofi-Aventis' $4 billion acquisition of Merck's 50 percent interest in Merial Limited in 2009.
Advised Sanofi-Aventis SA in its approximately $1.9 billion acquisition of US healthcare company Chattem Inc.
Advised Bioton S.A. in a groundbreaking supply and distribution agreement between Bioton and its subsidiary SciGen Ltd. and Bayer Healthcare Company Limited. The agreement allows Bayer to acquire the right to market and distribute insulin produced by Bioton and SciGen Ltd.